Newsfeeds - Spark Newswire

1 minute read

Barclays Initiates Coverage On Nurix Therapeutics with Overweight Rating, Announces Price Target of $20

Today, 11:06 AM

Barclays analyst Peter Lawson initiates coverage on Nurix Therapeutics (NASDAQ:NRIX) with a Overweight rating and announces Price Target of $20.

NRIX

1 minute read

Needham Maintains Buy on Nurix Therapeutics, Lowers Price Target to $31

By Benzinga Newsdesk

Today, 11:06 AM

Needham analyst Gil Blum maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and lowers the price target from $32 to $31.

NRIX

1 minute read

Nurix Therapeutics Q4 EPS $(0.87) Misses $(0.79) Estimate

By Bill Haddad

Today, 11:06 AM

Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.79) by 10.13 percent. This is a 2.35 percent decrease over losses of $(0.85) per share

NRIX

3 minute read

Nurix Therapeutics Presents Clinical Results From Novel BTK Degrader (NX-2127) At 64th American Society Of Hematology (ASH) Annual Meeting

By Michael Horton

Today, 11:06 AM

Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today presented

NRIX

3 minute read

Nurix Announces Initial NX-1607 Phase 1 Data Presented At The 37th Annual Meeting Of The Society For Immunotherapy Of Cancer Demonstrating Targeted CBL-B Inhibition In Patients With Advanced Malignancies

By Benzinga Newsdesk

Today, 11:06 AM

Biomarker results are a positive demonstration of target engagement for this first-in-class CBL-B inhibitor Biomarker levels achieved with NX-1607 treatment correspond to levels associated with potent anti-tumor

NRIX

2 minute read

Cathie Wood Loads Up Over $6.7M In Adobe Stock As It Tumbles 27% In A Month Over Figma Deal

By Bhavik Nair

Today, 11:06 AM

Cathie Wood-led ARK Investment Management bought over 23,000 shares of software maker Adobe Inc (NASDAQ: ADBE) through the

ADBE

1 minute read

Nurix Therapeutics Q3 EPS $(0.90) Beats $(0.98) Estimate, Sales $10.79M Miss $12.08M Estimate

By Benzinga Newsdesk

Today, 11:06 AM

Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(0.98) by 8.16 percent. This is a 38.46 percent decrease over losses of $(0.65) per share from

NRIX

5 minute read

Why SOBR Safe Shares Surged Around 233%; Here Are 68 Biggest Movers From Yesterday

By Lisa Levin

Today, 11:06 AM

Gainers

$APE

5 minute read

Tesla, Twitter And 76 Biggest Movers From Friday

By Lisa Levin

Today, 11:06 AM

Gainers Seritage Growth Properties (NYSE: SRG) shares surged 80.3% to settle at $10.96 after the company appointed Adam Metz as Chairman. Preliminary proxy materials also indicated the board recommended shareholders to approve a proposed plan sale.

ABEO

1 minute read

HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Lowers Price Target to $54

By Benzinga Newsdesk

Today, 11:06 AM

HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and lowers the price target from $60 to $54.

NRIX